Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

NCT02128932 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02128932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02128932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
August 4, 2014
Completion date
September 3, 2015
Enrollment
1,089 (actual)
Sites
231

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2